Quantcast
Last updated on April 19, 2014 at 7:46 EDT

Latest Pyoderma gangrenosum Stories

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...

2012-10-22 22:44:23

Provide new insights on Infliximab use, disease characteristics, fistulizing Crohn's disease Three separate studies presented today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas help to advance understanding of the differences between African American and Caucasian patients with Inflammatory Bowel Disease (IBD) and provide clinicians with new insight on how racial disparities involving disease characteristics, infliximab use, and...

2008-09-23 03:00:09

By Farhi, David Wallach, Daniel The neutrophilic dermatoses (ND) may present with pustules, plaques, ulcerations, and general malaise. They are secondary to the invasion of the skin by normal polymorphonuclear leukocytes in the absence of infection. ND are often associated with particular systemic diseases. The management of affected patients is reviewed, with a focus on nursing care. David Farhi Neutrophilic dermatoses (ND) are a group of diseases characterized by the presence of a non-...